FDA (CDER)
GUIDANCE FINAL
Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates: Guidance for Industry
Published: 9/8/2026Detected: 9/5/2026
Summary preview
Establishes temporary FDA policy for compounding certain starter parenteral nutrition products intended for neonates, aiming to maintain supply while emphasizing safety and quality expectations for compounded drug…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountpediatrics
gastroenterology
#starter parenteral nutrition
#neonates
#compounding
#parenteral nutrition
#quality controls
Official Source Document Source Verified
Access the original document directly from FDA CDER.
More from FDA (CDER)
- E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification; and Appendix to the Implementation Guide — Backwards and Forwards Compatibility10/1/2026
- Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling9/2/2026
- Evaluation of Therapeutic Equivalence8/21/2026
- Determining Whether to Submit an ANDA or a 505(b)(2) Application8/17/2026
- Container Closure Systems for Human Drugs and Biological Products8/13/2026